Amgen Orders Independent Reanalysis of Tavneos Data by Duke Clinical Research Institute
Amgen Inc. has contracted the Duke Clinical Research Institute to perform an independent reexamination of the clinical data supporting Tavneos, a rare-disease therapy facing potential removal from the U.S. market after regulators raised concerns that data submitted by the drug's former manufacturer may have been manipulated. Amgen plans to file the…